pre-IPO PHARMA

COMPANY OVERVIEW

Prokaryotics is a start-up company resulting from the licensing of several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.


LOCATION

  • Union, NJ, USA

  • THERAPEUTIC AREAS

  • Infectious Disease

  • WEBSITE

    http://prokaryotics.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 21, 2019

    Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds


    For More Press Releases


    Google Analytics Alternative